Scholarlink

<p>In this study, we developed a digital twin for SARS-CoV-2 by integrating diverse data and metadata with multiple data types and processing strategies, including machine learning, natural language processing, protein structural modeling, and protein sequence language modeling. This approach enabled us to computationally design neutralizing antibodies against over 1300 historical strains of SARS-CoV-2, encompassing 64 mutations in the receptor binding domain (RBD) region. 70 AI-designed antibodies were experimentally validated through binding assay and real viral neutralization assays against various strains, including later Omicron strains do not present in the initial design database. 14% of these antibodies exhibited strong reactivity against the RBD of multiple strains, achieving triple cross-binding hit rates using ELISA assay. 10 antibodies neutralized the cytopathic effects (CPE) of the Delta strain at IC50 values of &lt; 10&#xa0;µg/ml, and one antibody neutralized the CPE of Omicron. These findings demonstrate the potential of our approach to influence future therapeutic design for existing virus strains and predict hidden patterns in viral evolution that AI can leverage to develop emerging antiviral treatments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

AI designed, mutation resistant broad neutralizing antibodies against multiple SARS-CoV-2 strains

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月3日

查看全文
  • Yue Kang,
  • Kevin Jin,
  • Lurong Pan

摘要

In this study, we developed a digital twin for SARS-CoV-2 by integrating diverse data and metadata with multiple data types and processing strategies, including machine learning, natural language processing, protein structural modeling, and protein sequence language modeling. This approach enabled us to computationally design neutralizing antibodies against over 1300 historical strains of SARS-CoV-2, encompassing 64 mutations in the receptor binding domain (RBD) region. 70 AI-designed antibodies were experimentally validated through binding assay and real viral neutralization assays against various strains, including later Omicron strains do not present in the initial design database. 14% of these antibodies exhibited strong reactivity against the RBD of multiple strains, achieving triple cross-binding hit rates using ELISA assay. 10 antibodies neutralized the cytopathic effects (CPE) of the Delta strain at IC50 values of < 10 µg/ml, and one antibody neutralized the CPE of Omicron. These findings demonstrate the potential of our approach to influence future therapeutic design for existing virus strains and predict hidden patterns in viral evolution that AI can leverage to develop emerging antiviral treatments.